Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: Impact of changing disease epidemiology on contemporary trial design

Head and Neck

Volumn 37, Issue 11, 2015, Pages 1583-1589

  Rodriguez, Cristina P ^a   Adelstein, David J ^b   Rybicki, Lisa A ^b   Savvides, Panayiotis ^c   Saxton, Jerrold P ^b   Koyfman, Shlomo A ^b   Greskovich, John F ^b   Yao, Min ^d   Scharpf, Joseph ^b   Lavertu, Pierre ^d   Wood, Benjamin G ^b   Burkey, Brian B ^b   Lorenz, Robert R ^b   Rezaee, Rod P ^d   Zender, Chad A ^d   Ives, Denise I ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

chemoradiation; head and neck cancer; human papillomavirus (HPV); oropharynx; squamous cell carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG SAFETY; DYSPHAGIA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEARING IMPAIRMENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NECK DISSECTION; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DERMATITIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; WART VIRUS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEAD AND NECK NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NONPARAMETRIC TEST; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RADIOTHERAPY DOSAGE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84944046798     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23794     Document Type: Article

References (22)

1. Adelstein DJ, Li Y, Adams GL, et al., An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
2. Forastiere AA, Goepfert H, Maor M, et al., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
3. Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group,. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
4. Adelstein DJ, Rodriguez CP,. Current and emerging standards of concomitant chemoradiotherapy. Semin Oncol 2008; 35: 211-220.
5. Brockstein B, Haraf DJ, Rademaker AW, et al., Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15: 1179-1186.
6. Posner MR, Haddad RI, Wirth L, et al., Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004; 31: 778-785.
7. Adelstein DJ, Saxton JP, Rybicki LA, et al., Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006; 24: 1064-1071.
8. Ang KK, Harris J, Garden AS, et al., Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 2005; 23: 3008-3015.
9. Chaturvedi AK, Engels EA, Pfeiffer RM, et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
10. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML,. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612-619.
11. Weinberger PM, Yu Z, Haffty BG, et al., Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747.
12. Rischin D, Young RJ, Fisher R, et al., Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148.
13. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
14. Adelstein DJ, Rodriguez CP,. Human papillomavirus: changing paradigms in oropharyngeal cancer. Curr Oncol Rep 2010; 12: 115-120.
15. Benard VB, Johnson CJ, Thompson TD, et al., Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer 2008; 113(10 Suppl): 2910-2918.
16. Cohen EEW, Karrison T, Kocherginsky M, et al., DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2012;30(suppl; abstr 5500).
17. Haddad R, O'Neill A, Rabinowits G, et al., Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013; 14: 257-264.
18. Adelstein DJ, Ridge JA, Gillison ML, et al., Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, DC. Head Neck 2009; 31: 1393-1422.
19. Ang KK,. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol 2004; 22: 4657-4659.
20. Loong HH, Ma BB, Leung SF, et al., Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol 2012; 104: 300-304.
21. Videtic GM, Stitt LW, Dar AR, et al., Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003; 21: 1544-1549.
22. Browman GP, Wong G, Hodson I, et al., Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993; 328: 159-163.